The Price Tag of Scientific Fraud

Each paper retracted because of research misconduct costs taxpayers roughly $400,000, according to a report.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, JON SULLIVANIt’s presumed that research misconduct wastes resources, many of them given to scientists through federal dollars. Ferric Fang of the University of Washington and his colleagues quantified just how much fraud costs the government in a new report published yesterday (August 14) in eLife.

It turns out that every paper retracted because of research misconduct costs about $400,000 in funds from the US National Institutes of Health (NIH)—totaling $58 million for papers retracted between 1992 and 2012. The authors pointed out that this total represents a fraction of a percent of the NIH budget for these years.

And scientific fraud incurs additional costs. “The damage to researchers’ careers (who in some cases have done nothing wrong themselves), the institutional costs of investigating suspected fraud, the misdirection of public policy, and the misleading of other scientists who pursue false leads are other important costs,” Fang told Retraction Watch.

Still, compared to other government agencies, research misconduct is comparatively small, and less than what Fang had expected. “When one compares the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies